Timothy E. Morris

Timothy E. Morris is Chief Operating Officer and an internal Director of the Company.  He is the Managing Member of Aacolade Pharma LLC, a boutique advisory firm providing financing, corporate development, operating and governance consulting services to biotech and pharmaceutical companies.  He previously served as the Chief Financial Officer of Opthea Limited (Nasdaq, ASX: OPT), as the Chief Operating Officer and Chief Financial Officer of Humanigen, Inc. (Nasdaq: HGEN), and as Chief Financial Officer of Iovance Biotherapeutics, (Nasdaq: IOVA), AcelRx Pharmaceuticals, Inc (Nasdaq: ACRX), and VIVUS, Inc (Nasdaq: VVUS).   During his 25-year career he has raised over $3.0 billion in equity and convertible securities for multiple companies.  He has extensive deal experience with over 105 transactions and combined value over $6.3 billion.  His biotech experience includes clinical trial to commercial stage companies developing small molecules, biologics and cell therapy.  In addition to Humanetics, Mr. Morris currently serves as a Non-Executive Director for DBV Technologies S.A. (Nasdaq: DBVT, Euronext: DBV – ISIN: FR0010417345) and Aquestive Therapeutics, Inc. (Nasdaq: AQST).  He is a CPA (retired) and began his career from Chico State with Ernst & Young in Silicon Valley.

Mr. Morris has served as a member of the Board of Directors since 2021.